The Pittsburgh Cancer Institute (PCI) is a multidisciplinary program in cancer research, prevention and control, early diagnosis and treatment, education and clinical care. The PCI was formed by a consortium of the University of Pittsburgh, Carnegie Mellon University and the six hospitals affiliated with the Medical and Health Care Division of the University of Pittsburgh. The PCI maintains programs in the areas of: medical, surgical and radiation oncology along with multidisciplinary disease oriented programs in breast cancer, colon cancer, AIDS, cancer in transplant recipients, bone marrow transplantation, head and neck cancers, urologic cancer, brain tumors and melanoma. Basic research programs are functioning in the areas of molecular oncology, biochemistry and cell biology, immunology and experimental therapeutics. In addition, programs have been developed in epidemiology and preventive oncology, nursing and patient care services and behavioral medicine in oncology. The PCI maintains sixteen shared facilities to assist cancer researchers including: biostatistics unit, data center, protocol office, immunologic monitoring and diagnostic laboratory, serum and tissue bank, hybridoma facility, nuclear magnetic resonance, flow cytometry, protein sequencing, DNA sequencing and synthesis, crystallography, animal facility, glassware facility, protein synthesis, molecular genetics facility and immunohistology and special procedures laboratory. This application requests CORE SUPPORT for the Pittsburgh Cancer Institute's programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA047904-01
Application #
3101852
Study Section
Cancer Center Support Grant Review Committee (CCS)
Project Start
1988-08-01
Project End
1991-07-31
Budget Start
1988-08-01
Budget End
1989-07-31
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Overall Medical
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Toptan, Tuna; Abere, Bizunesh; Nalesnik, Michael A et al. (2018) Circular DNA tumor viruses make circular RNAs. Proc Natl Acad Sci U S A 115:E8737-E8745
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682
Vendetti, Frank P; Karukonda, Pooja; Clump, David A et al. (2018) ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 128:3926-3940
Lontos, Konstantinos; Tsagianni, Anastasia; Yuan, Jian-Min et al. (2018) Location matters in early stage nodal diffuse large B-cell lymphoma. Leuk Lymphoma :1-4
Correa, Andres F; Toussi, Amir; Amin, Milon et al. (2018) Small Renal Masses in Close Proximity to the Collecting System and Renal Sinus Are Enriched for Malignancy and High Fuhrman Grade and Should Be Considered for Early Intervention. Clin Genitourin Cancer 16:e729-e733
Wang, Yi-Jun; Fletcher, Rochelle; Yu, Jian et al. (2018) Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis 5:194-203
Bakkenist, Christopher J; Lee, James J; Schmitz, John C (2018) ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer. Clin Colorectal Cancer 17:255-257

Showing the most recent 10 out of 1187 publications